Acacia Pharma Becomes New Industry Supporter of the American Society of Anesthesiologists - Seite 2

“We are delighted to become an ASA Industry Supporter, the world’s pre-eminent organization representing anesthesiologists,” commented Acacia Pharma Chief Medical Officer Gabriel Fox, M.D. “This gives us a greatly valued opportunity to work with anesthesiologists across the country to improve the safety, outcomes and well-being of their patients. We look forward to a successful partnership for years to come and thank ASA for this opportunity.”

Contacts

Acacia Pharma Group plc Mike Bolinder, CEO Gary Gemignani, CFO [phone] / [phone] [e-mail]	International Media Mark Swallow, Frazer Hall, David Dible Citigate Dewe Rogerson [phone] [e-mail]
US Investors LifeSci Advisors Irina Koffler [phone] [e-mail]	Media in Belgium and the Netherlands Chris Van Raemdonck [phone] [e-mail]

About Acacia Pharma

Acacia Pharma is a hospital pharmaceutical company focused on the development and commercialization of new products aimed at improving the care of patients undergoing significant treatments such as surgery, other invasive procedures, or cancer chemotherapy. The Company has identified important and commercially attractive unmet needs in these areas that its product portfolio aims to address.

Acacia Pharma's first product, BARHEMSYS (amisulpride injection) is available in the US for the management of postoperative nausea & vomiting (PONV).

BYFAVO (remimazolam) for injection, a very rapid onset/offset IV benzodiazepine sedative is approved and launched in the US for use during invasive medical procedures in adults lasting 30 minutes or less, such as colonoscopy and bronchoscopy. BYFAVO is in-licensed from Paion UK Limited for the US market.

APD403 (intravenous and oral amisulpride), a selective dopamine antagonist for chemotherapy induced nausea & vomiting (CINV) has successfully completed one proof-of-concept and one Phase 2 dose-ranging study in patients receiving highly emetogenic chemotherapy.

Acacia Pharma has its US headquarters in Indianapolis, IN and its R&D operations are centred in Cambridge, UK. The Company is listed on the Euronext Brussels exchange under the ISIN code GB00BYWF9Y76 and ticker symbol ACPH.

Acacia Pharma Group plc
The Officers’ Mess, Royston Road, Duxford, Cambridge, CB22 4QH, United Kingdom
Company number 9759376

www.acaciapharma.com